Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Univec (UNVC) -- Ignore unavailable to you. Want to Upgrade?

To: r. peter Dale who wrote (75)	11/5/1997 8:26:00 PM
From: Courtney Willfore	Read Replies (1) \| Respond to of 181

Peter: Two things- 1. My brother, who knows about my interest in Univec, recently interviewed with an NGO that is associated with UNICEF. He said that the guy actually mentioned Univec as the supplier (in the context of the Turner plans) for syringes in the upcoming, large disease eradication programs. As far as I know, there's been no official announcement of this yet. 2. First round of questions tapping your knowledge of neurodegenerative diseases and the immune system. Regarding clinically treating apoptosis following the immune activation: if macrophage induced cell death could be thwarted, wouldn't this sig. reduce damage?. Is it possible to locally interfere with activated macrophage? Are there steps along the apoptosis pathway susceptible to block? I wonder if a pharmacological agent could selectively block neurodegenerative apoptosis without interfering with cell death necessary for homeostasis. I'm debating the fields of immunology or neurobiology for graduate school. Thanks in advance. (Hurry up and pass those stones...) Courtney